



Nplate® (romiplostim) – New indication

- On January 28, 2021, the [FDA approved](#) Amgen's [Nplate \(romiplostim\)](#), to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation.
- Nplate is also approved for the treatment of thrombocytopenia in:
 - Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
 - Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- Efficacy studies of Nplate could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval for this indication was based on efficacy studies conducted in animals, Nplate's effect on platelet count in healthy human volunteers and on data supporting Nplate's effect on thrombocytopenia in patients with ITP and insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- The recommended dose of Nplate for acute radiation syndrome is 10 mcg/kg administered once as a subcutaneous injection. The dose should be administered as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray.
 - Nplate should be administered regardless of whether a complete blood count can be obtained. A patient's absorbed whole body radiation dose (ie, level of radiation exposure) should be estimated based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.
 - Refer to the Nplate drug label for dosing for ITP.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.